Zostrix on the Shelves

by / Sunday, 01 July 2007 / Published in News

On 1st July 2007 the big three pharmaceutical wholesalers took stock of both Zostrix and Zostrix HP. As a result retail pharmacies should have stock soon after that date. This is good news for those suffering the pain associate with osteoarthritis, diabetic neuropathy and post-herpetic neuralgia.

ZOSTRIX is registered by the Australian authorities in two strengths for the treatment of pain. The 0.025% cream is approved for pain associated with osteoarthritis and the 0.075% formulation is approved for the relief of neuropathic pain.

LINK Pharmaceuticals’ Managing Director Mr. John Bacon commented that “ZOSTRIX is a highly effective treatment with good clinical evidence of efficacy. The side effect profile is excellent and we expect the product to be an important part of our growing portfolio.” For more information, visit